Description

ABHIRISE 20 MG

Indications

ABHIRISE 20 MG is a pharmaceutical formulation that combines two active ingredients: Rabeprazole and Levosulpiride. This medication is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and functional dyspepsia. It is effective in alleviating symptoms associated with excessive gastric acid secretion, such as heartburn, acid regurgitation, and abdominal discomfort. The combination of these two agents enhances therapeutic efficacy, addressing both acid-related symptoms and gastrointestinal motility disorders.

Mechanism of Action

Rabeprazole is a proton pump inhibitor (PPI) that exerts its effect by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cells. This inhibition leads to a significant reduction in gastric acid secretion, thereby promoting healing of the gastric mucosa and alleviating symptoms of acid-related disorders.

Levosulpiride, on the other hand, is an atypical antipsychotic that also possesses prokinetic properties. It acts as a dopamine D2 receptor antagonist, which enhances gastrointestinal motility by increasing the frequency of contractions in the upper gastrointestinal tract. This dual action not only helps in reducing gastric acidity but also improves gastric emptying, making it beneficial for patients with dyspeptic symptoms.

Pharmacological Properties

The pharmacokinetics of ABHIRISE 20 MG is characterized by rapid absorption of both Rabeprazole and Levosulpiride. Rabeprazole reaches peak plasma concentrations within 1 to 2 hours after oral administration, with a bioavailability of approximately 52% due to first-pass metabolism. It has a half-life of about 1 to 2 hours, and its effects can last up to 24 hours, allowing for once-daily dosing.

Levosulpiride is also rapidly absorbed, with peak plasma concentrations occurring within 2 to 3 hours post-ingestion. Its bioavailability is influenced by food intake, and it is primarily metabolized in the liver. The elimination half-life is approximately 6 to 8 hours, which supports its use in managing symptoms throughout the day.

Contraindications

ABHIRISE 20 MG is contraindicated in patients with known hypersensitivity to Rabeprazole, Levosulpiride, or any of the excipients in the formulation. Additionally, it should not be used in individuals with a history of gastrointestinal bleeding, severe liver impairment, or those with pheochromocytoma due to the potential for exacerbating symptoms. Caution is advised in patients with renal impairment, as dosage adjustments may be necessary.

Side Effects

Common side effects associated with ABHIRISE 20 MG include headache, dizziness, nausea, vomiting, and abdominal pain. Gastrointestinal disturbances such as diarrhea or constipation may also occur. In rare cases, patients may experience more severe adverse effects, including allergic reactions, liver enzyme elevation, or extrapyramidal symptoms due to Levosulpiride. Long-term use of Rabeprazole may lead to vitamin B12 deficiency or an increased risk of gastrointestinal infections.

Dosage and Administration

The recommended dosage of ABHIRISE 20 MG for adults is one tablet taken orally once daily, preferably before meals. The duration of therapy may vary depending on the condition being treated, typically ranging from 4 to 8 weeks for GERD and peptic ulcers. It is essential to follow the prescribed regimen and not exceed the recommended dose to minimize the risk of adverse effects.

Interactions

ABHIRISE 20 MG may interact with various medications, potentially altering their effectiveness or increasing the risk of side effects. Notable interactions include the potential for decreased absorption of drugs that require an acidic environment for optimal bioavailability, such as ketoconazole and certain antiretrovirals. Levosulpiride may enhance the effects of central nervous system depressants, leading to increased sedation. It is advisable to inform healthcare providers of all medications being taken to assess for possible interactions.

Precautions

Patients should be monitored closely during treatment with ABHIRISE 20 MG, particularly those with a history of cardiovascular disease, as Levosulpiride may affect cardiac conduction. Caution is also warranted in elderly patients and those with a history of seizures. Long-term use of Rabeprazole should be periodically evaluated to assess the necessity of continued therapy, especially in light of potential adverse effects associated with prolonged acid suppression.

Clinical Studies

Clinical studies have demonstrated the efficacy of ABHIRISE 20 MG in treating GERD and functional dyspepsia. A randomized controlled trial indicated significant improvement in symptom relief and quality of life for patients treated with the combination of Rabeprazole and Levosulpiride compared to those receiving monotherapy. Furthermore, studies have shown that the combination therapy enhances gastric motility, thereby providing additional benefits in managing dyspeptic symptoms.

Conclusion

ABHIRISE 20 MG represents a valuable therapeutic option for patients suffering from acid-related gastrointestinal disorders. The synergistic effects of Rabeprazole and Levosulpiride not only address the underlying causes of symptoms but also improve gastrointestinal motility, enhancing overall patient outcomes. As with any medication, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective treatment.